DK1781657T3 - Medikamenter med hm74a-receptor aktivitet - Google Patents

Medikamenter med hm74a-receptor aktivitet

Info

Publication number: DK1781657T3
Authority: DK; Denmark
Prior art keywords: medicines; receptor activity; hm74a receptor; hm74a; activity
Prior art date: 2004-02-14

Application number

DK05707363.7T

Other languages

English (en)

Inventor

Ivan Leo Pinto

Shahzad Sharooq Rahman

Neville Hubert Nicholson

Original Assignee

Glaxosmithkline Ip Dev Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-14

Filing date

2005-02-10

Publication date

2013-06-10

2004-02-14 Priority claimed from GB0403282A external-priority patent/GB0403282D0/en

2004-10-22 Priority claimed from GB0423562A external-priority patent/GB0423562D0/en

2004-12-24 Priority claimed from GB0428375A external-priority patent/GB0428375D0/en

2005-02-10 Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd

2013-06-10 Application granted granted Critical

2013-06-10 Publication of DK1781657T3 publication Critical patent/DK1781657T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK05707363.7T 2004-02-14 2005-02-10 Medikamenter med hm74a-receptor aktivitet DK1781657T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0403282A GB0403282D0 (en)	2004-02-14	2004-02-14	Chemical compounds
GB0423562A GB0423562D0 (en)	2004-10-22	2004-10-22	Novel compounds
GB0428375A GB0428375D0 (en)	2004-12-24	2004-12-24	Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en)	2004-02-14	2005-02-10	Medicaments with hm74a receptor activity

Publications (1)

Publication Number	Publication Date
DK1781657T3 true DK1781657T3 (da)	2013-06-10

Family

ID=34864831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05707363.7T DK1781657T3 (da)	2004-02-14	2005-02-10	Medikamenter med hm74a-receptor aktivitet

Country Status (26)

Country	Link
US (5)	US7713982B2 (da)
EP (1)	EP1781657B1 (da)
JP (2)	JP5001012B2 (da)
KR (1)	KR101100601B1 (da)
CN (2)	CN101103030B (da)
AR (1)	AR047669A1 (da)
AU (1)	AU2005212816C1 (da)
BR (1)	BRPI0507604A (da)
CA (1)	CA2556073C (da)
CY (1)	CY1114022T1 (da)
DK (1)	DK1781657T3 (da)
ES (1)	ES2406732T3 (da)
HK (1)	HK1104530A1 (da)
HR (1)	HRP20130406T1 (da)
IL (1)	IL177051A (da)
MA (1)	MA28357A1 (da)
MY (1)	MY148937A (da)
NO (1)	NO337281B1 (da)
NZ (1)	NZ548496A (da)
PE (1)	PE20060317A1 (da)
PL (1)	PL1781657T3 (da)
PT (1)	PT1781657E (da)
SG (1)	SG157242A1 (da)
SI (1)	SI1781657T1 (da)
TW (1)	TWI350289B (da)
WO (1)	WO2005077950A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1230243T1 (sl) *	1999-11-12	2009-08-31	Biogen Idec Inc	Policikloalkilpurini kot antagonisti adenozinskega receptorja
AR039385A1 (es)	2002-04-19	2005-02-16	Astrazeneca Ab	Derivados de tioxantina como inhibidores de la mieloperoxidasa
EP1603585A2 (en)	2003-03-14	2005-12-14	Bristol-Myers Squibb Company	Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
DK1781657T3 (da) *	2004-02-14	2013-06-10	Glaxosmithkline Ip Dev Ltd	Medikamenter med hm74a-receptor aktivitet
AR054998A1 (es)	2004-12-03	2007-08-01	Schering Corp	Piperazinas sustituidas como antagonistas de cb1, composicion farmaceutica y uso del compuesto para la manufactura de medicamentos
MY140748A (en)	2004-12-06	2010-01-15	Astrazeneca Ab	Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en)	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en)	2005-05-17	2010-05-25	Schering Corporation	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
EP1896396A1 (en) *	2005-06-14	2008-03-12	F.Hoffmann-La Roche Ag	Anthranilic acid derivatives
SI1901731T1 (sl)	2005-06-28	2011-07-29	Merck Sharp & Dohme	Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
EP2272848B1 (en) *	2005-08-10	2012-12-26	Glaxosmithkline LLC	Xanthine derivatives as selective HM74A agonists
CA2637717A1 (en)	2006-01-20	2007-08-02	Schering Corporation	Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
ATE469905T1 (de) *	2006-05-23	2010-06-15	Hoffmann La Roche	Pyridopyrimidinonderivate
TW200804383A (en)	2006-06-05	2008-01-16	Astrazeneca Ab	New compounds
TWI423978B (zh)	2006-06-23	2014-01-21	Incyte Corp	作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（二）
KR20090025261A (ko)	2006-06-23	2009-03-10	인사이트 코포레이션	Ｈｍ７４ａ 아고니스트로서의 퓨리논 유도체
MX2009010218A (es) *	2007-03-23	2009-10-19	Hoffmann La Roche	Derivados de aza-piridopirimidinona.
US9163024B2 (en) *	2008-12-08	2015-10-20	Glaxosmithkline Llc	Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione
EP2379547A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Bicyclic pyranone derivatives as nicotinic acid receptor agonists
CN102276610B (zh) *	2011-05-04	2013-01-09	北京工业大学	N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) *	2013-07-29	2015-07-22	上海万巷制药有限公司	8-氯茶碱的制备方法
MX380301B (es) *	2015-01-30	2025-03-12	Shanton Pharma Pte Ltd	Prevención o tratamiento de enfermedades urinarias o gotosas.
CN104892610B (zh) *	2015-05-27	2016-08-24	福建师范大学	一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) *	2016-03-28	2016-06-01	浙江诚意药业股份有限公司	一种黄嘌呤化合物的制备方法
CA3032229A1 (en)	2016-07-27	2018-02-01	Hartis-Pharma Sa	Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) *	2016-11-23	2020-07-24	上海皓元医药股份有限公司	一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
BR112019014270B1 (pt)	2017-01-10	2023-12-26	Bayer Cropscience Aktiengesellschaft	Derivados de heterociclo, seus usos, formulação agroquímica, e método para controlar pragas animais
US20220380370A1 (en) *	2019-09-25	2022-12-01	Goldfinch Bio, Inc.	Xanthine cb1 inhibitors
CN112724141A (zh) *	2021-01-21	2021-04-30	南京艾美斐生物医药科技有限公司	一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) *	2021-07-21	2021-09-17	北京矿冶研究总院	阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024179463A1 (zh) *	2023-02-27	2024-09-06	珊顿医药科技新加坡公司	化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2797220A (en) *	1954-12-02	1957-06-25	Univ Michigan	Substituted paraxanthines
US4847377A (en) *	1985-05-13	1989-07-11	Schering Corporation	Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) *	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
IL100088A (en) *	1990-11-21	1995-07-31	Smithkline Beecham Corp	FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU3725893A (en) *	1992-02-21	1993-09-13	Smithkline Beecham Corporation	TNF inhibitors
ATE230990T1 (de)	1992-03-04	2003-02-15	Cell Therapeutics Inc	Enantiomere hydroxylierte xanthinverbindungen
US6693105B1 (en)	1992-11-16	2004-02-17	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
US6469017B1 (en)	1998-01-16	2002-10-22	Cell Therapeutics, Inc.	Method of inhibiting interleukin-12 signaling
US5804584A (en)	1992-11-16	1998-09-08	Cell Therapeutics, Inc.	Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en)	1992-11-16	1995-12-05	Cell Therapeutics, Inc.	Substituted long chain alcohol xanthine compounds
IL109161A0 (en)	1993-03-31	1994-06-24	Cell Therapeutics Inc	Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en)	1993-04-05	1997-09-23	Cell Therapeutics, Inc.	Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en)	1993-04-09	1994-10-27	Cell Therapeutics, Inc.	Ring-substituted cell signaling inhibitors
AU1868195A (en)	1994-01-28	1995-08-15	Cell Therapeutics, Inc.	Cell signaling inhibitors
US6103730A (en)	1994-03-24	2000-08-15	Cell Therapeutics, Inc.	Amine substituted compounds
US6780865B1 (en)	1994-02-18	2004-08-24	Cell Therapeutics, Inc.	Compounds having selective hydrolytic potentials
US6878715B1 (en)	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
CA2183562A1 (en)	1994-02-18	1995-08-24	J. Peter Klein	Intracellular signalling mediators
US5807861A (en)	1994-03-24	1998-09-15	Cell Therapeutics, Inc.	Amine substituted xanthinyl compounds
US5801182A (en)	1994-03-24	1998-09-01	Cell Therapeutics, Inc.	Amine substituted compounds
US6323201B1 (en)	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) *	1997-10-17	2001-05-30	Smithkline Beecham Corp	Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
ATE312102T1 (de)	1999-04-09	2005-12-15	Cell Therapeutics Inc	Xanthinderivate und analoge als zellsignalisierung inhibitoren
US20030207901A1 (en)	1999-07-27	2003-11-06	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
KR100502757B1 (ko) *	1999-08-31	2005-07-22	반더빌트유니버시티	Ａ２ｂ 아데노신 수용체의 선택적인 길항제
AU2001276023A1 (en) *	2000-07-21	2002-02-05	Mark B Lyles	Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) *	2000-07-28	2003-01-24	Inside Technologies	Dispositif electronique portable comprenant plusieurs circuits integres sans contact
CA2422820A1 (en) *	2000-09-19	2002-03-28	Novimmune S.A.	Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
ATE430749T1 (de)	2001-02-24	2009-05-15	Boehringer Ingelheim Pharma	Xanthinderivate verwendung als arzneimittel sowie deren verfahren zur deren herstellung
AU2002242910A1 (en)	2001-04-11	2002-10-28	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
DK1781657T3 (da) *	2004-02-14	2013-06-10	Glaxosmithkline Ip Dev Ltd	Medikamenter med hm74a-receptor aktivitet
WO2006045564A1 (en)	2004-10-22	2006-05-04	Smithkline Beecham Corporation	Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en)	2004-10-22	2009-08-20	Richard Jonathan Daniel Hatley	Xanthine Derivatives with HM74A Receptor Activity
EP2272848B1 (en)	2005-08-10	2012-12-26	Glaxosmithkline LLC	Xanthine derivatives as selective HM74A agonists
EP1939197A1 (en) *	2006-12-22	2008-07-02	Schwarz Pharma Ag	8-ethinylxanthine derivatives as selective A2A receptor antagonists
US9163024B2 (en) *	2008-12-08	2015-10-20	Glaxosmithkline Llc	Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione
US20110065676A1 (en) *	2009-06-24	2011-03-17	Schering Corporation	Combination therapies comprising par1 antagonists with nar agonists

2005
- 2005-02-10 DK DK05707363.7T patent/DK1781657T3/da active
- 2005-02-10 ES ES05707363T patent/ES2406732T3/es not_active Expired - Lifetime
- 2005-02-10 JP JP2006552565A patent/JP5001012B2/ja not_active Expired - Fee Related
- 2005-02-10 EP EP05707363A patent/EP1781657B1/en not_active Expired - Lifetime
- 2005-02-10 KR KR1020067016277A patent/KR101100601B1/ko active IP Right Grant
- 2005-02-10 CN CN2005800114336A patent/CN101103030B/zh not_active Expired - Fee Related
- 2005-02-10 NZ NZ548496A patent/NZ548496A/en not_active IP Right Cessation
- 2005-02-10 CN CN2010102007350A patent/CN101863888B/zh not_active Expired - Fee Related
- 2005-02-10 US US10/589,474 patent/US7713982B2/en not_active Expired - Fee Related
- 2005-02-10 PL PL05707363T patent/PL1781657T3/pl unknown
- 2005-02-10 SI SI200531730T patent/SI1781657T1/sl unknown
- 2005-02-10 BR BRPI0507604-8A patent/BRPI0507604A/pt not_active Application Discontinuation
- 2005-02-10 SG SG200803771-5A patent/SG157242A1/en unknown
- 2005-02-10 CA CA2556073A patent/CA2556073C/en not_active Expired - Fee Related
- 2005-02-10 PT PT57073637T patent/PT1781657E/pt unknown
- 2005-02-10 WO PCT/EP2005/001449 patent/WO2005077950A2/en active Application Filing
- 2005-02-10 AU AU2005212816A patent/AU2005212816C1/en not_active Ceased
- 2005-02-11 PE PE2005000170A patent/PE20060317A1/es not_active Application Discontinuation
- 2005-02-14 TW TW094104133A patent/TWI350289B/zh not_active IP Right Cessation
- 2005-02-14 AR ARP050100512A patent/AR047669A1/es not_active Application Discontinuation
- 2005-02-14 MY MYPI20050527A patent/MY148937A/en unknown
2006
- 2006-07-24 IL IL177051A patent/IL177051A/en not_active IP Right Cessation
- 2006-08-11 MA MA29262A patent/MA28357A1/fr unknown
- 2006-09-13 NO NO20064151A patent/NO337281B1/no not_active IP Right Cessation
2007
- 2007-09-04 HK HK07109621.1A patent/HK1104530A1/xx not_active IP Right Cessation
2008
- 2008-02-12 JP JP2008030344A patent/JP5020848B2/ja not_active Expired - Fee Related
2009
- 2009-09-02 US US12/552,649 patent/US8394808B2/en not_active Expired - Fee Related
2010
- 2010-03-04 US US12/717,349 patent/US8268839B2/en not_active Expired - Fee Related
2013
- 2013-02-06 US US13/760,423 patent/US20130150383A1/en not_active Abandoned
- 2013-05-08 HR HRP20130406TT patent/HRP20130406T1/hr unknown
- 2013-05-29 CY CY20131100430T patent/CY1114022T1/el unknown
2014
- 2014-11-21 US US14/549,721 patent/US20150080418A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1114022T1 (el)	2016-07-27
PE20060317A1 (es)	2006-06-22
PT1781657E (pt)	2013-05-23
EP1781657A2 (en)	2007-05-09
US20070135456A1 (en)	2007-06-14
US20100010021A1 (en)	2010-01-14
CN101103030B (zh)	2010-10-13
PL1781657T3 (pl)	2013-08-30
AU2005212816A1 (en)	2005-08-25
AU2005212816C1 (en)	2010-03-04
CA2556073C (en)	2012-01-10
CN101103030A (zh)	2008-01-09
JP2007522176A (ja)	2007-08-09
US20100160354A1 (en)	2010-06-24
BRPI0507604A (pt)	2007-07-03
KR101100601B1 (ko)	2011-12-29
IL177051A0 (en)	2006-12-10
HRP20130406T1 (hr)	2013-06-30
NO337281B1 (no)	2016-02-29
EP1781657B1 (en)	2013-03-27
JP5020848B2 (ja)	2012-09-05
TW200536537A (en)	2005-11-16
MA28357A1 (fr)	2006-12-01
WO2005077950A3 (en)	2007-04-19
IL177051A (en)	2013-01-31
US20130150383A1 (en)	2013-06-13
NO20064151L (no)	2006-11-06
ES2406732T3 (es)	2013-06-07
US7713982B2 (en)	2010-05-11
AR047669A1 (es)	2006-02-01
CN101863888B (zh)	2012-07-18
US8394808B2 (en)	2013-03-12
KR20060126772A (ko)	2006-12-08
JP2008120831A (ja)	2008-05-29
TWI350289B (en)	2011-10-11
SG157242A1 (en)	2009-12-29
NZ548496A (en)	2010-02-26
HK1104530A1 (en)	2008-01-18
CA2556073A1 (en)	2005-08-25
SI1781657T1 (sl)	2013-07-31
US20150080418A1 (en)	2015-03-19
CN101863888A (zh)	2010-10-20
US8268839B2 (en)	2012-09-18
AU2005212816B2 (en)	2009-07-23
MY148937A (en)	2013-06-14
WO2005077950A2 (en)	2005-08-25
JP5001012B2 (ja)	2012-08-15

Publication	Publication Date	Title
DK1781657T3 (da)	2013-06-10	Medikamenter med hm74a-receptor aktivitet
NO20052027L (no)	2005-10-27	Katalysatorer
DK3581912T3 (da)	2021-07-26	Diagnoseindretninger med indbygget fluidik
DE602005007508D1 (de)	2008-07-24	Funktioneller zuckerersatz
DE602005020310D1 (de)	2010-05-12	Lanzette, lanzettenanordnung und lanzette-sensor-kombination
IL182586A0 (en)	2007-07-24	Xanthine derivatives with hm74a receptor activity
DK1854789T3 (da)	2013-10-21	Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet
DE602005021602D1 (de)	2010-07-15	Neigungsverstellvorrichtung
AT500849B8 (de)	2007-02-15	Harnstoffdosiervorrichtung
DK1858490T3 (da)	2012-07-23	Lægemiddelformer med forbedrede farmakokinetiske egenskaber
DE602007008831D1 (de)	2010-10-14	Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
DE602005021745D1 (de)	2010-07-22	Neigungsverstellvorrichtung
DE602005023894D1 (de)	2010-11-11	Rücklehnvorrichtung
DK1757293T3 (da)	2012-10-22	Bh4-responsiv hyperphenylalaninæmi-medikamenter
DK1594859T3 (da)	2010-10-11	Indazolamider med analgetisk aktivitet
FI20045506L (fi)	2006-06-30	Tulistimen rakenne
FI20045446L (fi)	2006-05-20	Sänky
SE0400111L (sv)	2005-07-21	Sensorarrangemang
ITVR20040025A1 (it)	2004-05-25	Struttura di letto
ITMI20050409U1 (it)	2006-05-30	Tappetino
ES1058102Y (es)	2005-02-16	Lentilla terapeutica.
ZA200703231B (en)	2008-10-29	Xanthine derivatives with HM74A receptor activity
IS8536A (is)	2006-09-06	Lyf með HM74A viðtakavirkni
DK1720557T3 (da)	2011-02-14	Hurtig-opløselig, smagsmaskeret tablet
SE0400213D0 (sv)	2004-02-04	Diurea Derivatives